China Breaks Ground On First Biomedical Plant
This article was originally published in PharmAsia News
China broke ground on what is to be the nation's first biological medicine manufacturing center, located in Shanghai. The manufacturer is to be Shanghai No. 1 Biochemical & Pharmaceutical, and the intent is to make products according to European Union specifications. The $17.5 million plant is expected to begin production in September 2009, on freeze-dried powder injections. A company official said the entire system is to be mechanized to prevent contamination. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.